Hyperbaric oxygen (HBO2) treatment for tissue damage
Hyperbaric oxygen treatment (HBOT) involves the systemic administration of pure gaseous oxygen under pressures greater than 1 atmosphere in a specialized chamber. Hyperbaric oxygen may also be administered in a multiplace chamber in which patients breathe 100% oxygen through a facemask or similar device with the surrounding air pressure increased to 2 to 3 times the atmospheric pressure.
Decision summary
HBOT is covered with conditions for sudden sensorineural hearing loss, acute acoustic trauma, and tissue damage. HBOT is not covered for all other indications.
See final findings and decision summary for detailed conditions of coverage.
Documentation
| Type | Materials |
|---|---|
| Current decision summary | |
| Update literature (2025) | |
| Assessment (2025) | |
| Assessment (2013) |
Assessment timeline
- Draft key questions published: August 29, 2024
- Public comment period: August 29 to September 12, 2024
- Final key questions: September 26, 2024
- Draft report published: January 7, 2025
- Public comment period: January 7 to February 5, 2025
- Final report published: February 21, 2025
- HTCC public meeting: March 21, 2025
- Draft findings and decision published: March 28, 2025
- Public comment period: March 28 to April 11, 2025
- Final findings and decision published: June 23, 2025